Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2020 / 05:30PM GMT
Release Date Price: $106.03 (+5.62%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Welcome to Global Healthcare Conference. I'm Jeff Hung, one of the Biotech analysts. (Operator Instruction] For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. (Operator Instructions) So for this session, we have from Neurocrine Biosciences, CEO, Kevin Gorman; and CFO, Matt Abernethy. Welcome, guys.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Welcome, Jeff, and thank you very much for the opportunity to speak here today.

Jeff Hung
Morgan Stanley, Research Division - Equity Analyst

Yes. So for those who may not be familiar with Neurocrine, can you provide a brief introduction?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Certainly. And before I start, Matt and I will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot